Research classified by Journal of Economic Literature (JEL) codes

2013

• Murray L. Aitken & Ernst R. Berndt & Barry Bosworth & Iain M. Cockburn & Richard Frank & Michael Kleinrock & Bradley T. Shapiro, 2013, "The Regulation of Prescription Drug Competition and Market Responses: Patterns in Prices and Sales following Loss of Exclusivity," NBER Chapters, National Bureau of Economic Research, Inc, "Measuring and Modeling Health Care Costs".
• Marco Ceccagnoli & Matthew J. Higgins & Vincenzo Palermo, 2013, "Behind the Scenes: Sources of Complementarity in R&D," NBER Working Papers, National Bureau of Economic Research, Inc, number 18795, Feb.
• Ernst R. Berndt & Iain M. Cockburn, 2013, "Price Indexes for Clinical Trial Research: A Feasibility Study," NBER Working Papers, National Bureau of Economic Research, Inc, number 18918, Mar.
• Murray L. Aitken & Ernst R. Berndt & Barry Bosworth & Iain M. Cockburn & Richard Frank & Michael Kleinrock & Bradley T. Shapiro, 2013, "The Regulation of Prescription Drug Competition and Market Responses: Patterns in Prices and Sales Following Loss of Exclusivity," NBER Working Papers, National Bureau of Economic Research, Inc, number 19487, Oct.
• Peter Arcidiacono & Paul B. Ellickson & Peter Landry & David B. Ridley, 2013, "Pharmaceutical Followers," NBER Working Papers, National Bureau of Economic Research, Inc, number 19522, Oct.
• Nathan Rosenberg & W. Edward Steinmueller, 2013, "Engineering knowledge," Industrial and Corporate Change, Oxford University Press and the Associazione ICC, volume 22, issue 5, pages 1129-1158, October.
• Leung, Vincent K.K. & Lau, Chi Keung Marco & Zhang, Zhe, 2013, "Explorative Versus Exploitative Alliances—Evidence From The Glass Industry In China," MPRA Paper, University Library of Munich, Germany, number 47065, Jan.
• Cassi, Lorenzo & Plunket, Anne, 2013, "Proximity, network formation and inventive performance: in search of the proximity paradox," MPRA Paper, University Library of Munich, Germany, number 47388, Jan.
• Blanco Orozco, Napoleón Vicente & Zuniga Gonzalez, Carlos Alberto, 2013, "Environmental Bio Economic Impact in Nicaragua," MPRA Paper, University Library of Munich, Germany, number 49357, May, revised 12 Jun 2013.
• Botero Degiovanni, Hernan, 2013, "The Effects of Drug Enforcement on Violence in Colombia 1999-2010: A Spatial Econometric Approach," MPRA Paper, University Library of Munich, Germany, number 49459, Sep.
• Kulvik, Martti & Tähtinen, Marja & Ylä-Anttila, Pekka, 2013, "Business and Intellectual Capital Development in Financial Riptide - Case Studies of Finnish Biotechnology and Pharmaceutical Companies Dispersing into Global Value Chains," ETLA Reports, The Research Institute of the Finnish Economy, number 17, Oct.
• Clément WILS, 2013, "La chimie verte: une nouvelle industrie de substitution GREEN CHEMISTRY: A NEW INDUSTRY OF SUBSTITUTE," Working Papers, Laboratoire de Recherche sur l'Industrie et l'Innovation. ULCO / Research Unit on Industry and Innovation, number 263, Feb.
• Irina Ipatova & Аnatoly Peresetsky, 2013, "Technical efficiency of Russian plastic and rubber production firms," Applied Econometrics, Russian Presidential Academy of National Economy and Public Administration (RANEPA), volume 32, issue 4, pages 71-92.
• Arpita Ghose & Chandrima Chakraborti, 2013, "The Relative Role of Imports and Exports in Explaining Productivity of Indian Bio-Pharmaceutical Firms: Evidence from Non Parametric Data Envelopment Analysis," Foreign Trade Review, , volume 48, issue 2, pages 165-201, May, DOI: 10.1177/0015732513481657.
• Christian Garavaglia & Franco Malerba & Luigi Orsenigo & Michele Pezzoni, 2013, "Technological Regimes and Demand Structure in the Evolution of the Pharmaceutical Industry," Economic Complexity and Evolution, Springer, in: Andreas Pyka & Esben Sloth Andersen, "Long Term Economic Development", DOI: 10.1007/978-3-642-35125-9_4.
• Frank Lichtenberg, 2013, "The impact of new (orphan) drug approvals on premature mortality from rare diseases in the United States and France, 1999–2007," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), volume 14, issue 1, pages 41-56, February, DOI: 10.1007/s10198-011-0349-4.
• Saradindu Bhaduri & Thomas Brenner, 2013, "Examining the determinants of drug launch delay in pre-TRIPS India," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), volume 14, issue 5, pages 761-773, October, DOI: 10.1007/s10198-012-0422-7.
• Roberta Piergiovanni & Enrico Santarelli, 2013, "The more you spend, the more you get? The effects of R&D and capital expenditures on the patenting activities of biotechnology firms," Scientometrics, Springer;Akadémiai Kiadó, volume 94, issue 2, pages 497-521, February, DOI: 10.1007/s11192-012-0711-z.
• Lili Wang & Ad Notten & Alexandru Surpatean, 2013, "Interdisciplinarity of nano research fields: a keyword mining approach," Scientometrics, Springer;Akadémiai Kiadó, volume 94, issue 3, pages 877-892, March, DOI: 10.1007/s11192-012-0856-9.
• Krogmann, Yin & Riedel, Nadine & Schwalbe, Ulrich, 2013, "Inter-firm R&D networks in pharmaceutical biotechnology: What determines firm's centrality-based partnering capability," FZID Discussion Papers, University of Hohenheim, Center for Research on Innovation and Services (FZID), number 75-2013.

2012

• Toshiaki Iizuka, 2012, "Physician Agency and Adoption of Generic Pharmaceuticals," American Economic Review, American Economic Association, volume 102, issue 6, pages 2826-2858, October.
• Craig L. Garthwaite, 2012, "The Economic Benefits of Pharmaceutical Innovations: The Case of Cox-2 Inhibitors," American Economic Journal: Applied Economics, American Economic Association, volume 4, issue 3, pages 116-137, July.
• Abe Dunn, 2012, "Drug Innovations and Welfare Measures Computed from Market Demand: The Case of Anti-cholesterol Drugs," American Economic Journal: Applied Economics, American Economic Association, volume 4, issue 3, pages 167-189, July.
• Ljumovic, Isidora & Cvijanovic, Janko & Lazic, Jelena, 2012, "Valuation Of Biotechnology Companies: Real Options Approach Under Uncertainty," Economics of Agriculture, Institute of Agricultural Economics, volume 59, issue 01, pages 1-12, April, DOI: 10.22004/ag.econ.123958.
• Frank Lichtenberg & Billie Pettersson, 2012, "The Impact of Pharmaceutical Innovation on Longevity and Medical Expenditure in Sweden, 1997-2010: Evidence from Longitudinal, Disease-Level Data," CESifo Working Paper Series, CESifo, number 3894.
• Kurt R. Brekke & Tor Helge Holmås & Odd Rune Straume, 2012, "Margins and Market Shares: Pharmacy Incentives for Generic Substitution," CESifo Working Paper Series, CESifo, number 4055.
• Francesca Spigarelli & Hao Way, 2012, "The rising Chinese pharmaceutical industry: local champions vs global players," Working Papers, c.MET-05 - Centro Interuniversitario di Economia Applicata alle Politiche per L'industria, lo Sviluppo locale e l'Internazionalizzazione, number 1206, Oct.
• Juan Gonzalo Zapata & Sergio Bernal & Jairo Castillo & Katherine Garz�n, 2012, "Hacia una política integral de medicamentos biotecnológicos en Colombia," Cuadernos de Fedesarrollo, Fedesarrollo, number 9896, Feb.
• Anderson, Simon & Renault, Régis & Ciliberto, Federico & Liaukonyte, Jura, 2012, "Push-Me Pull-You: Comparative Advertising in the OTC Analgesics Industry," CEPR Discussion Papers, C.E.P.R. Discussion Papers, number 8988, May.
• Berndt, Ernst R & Dubois, Pierre, 2012, "Impacts of Patent Expiry and Regulatory Policies on Daily Cost of Pharmaceutical Treatments: OECD Countries, 2004-2010," CEPR Discussion Papers, C.E.P.R. Discussion Papers, number 9140, Sep.
• Mario Coccia, 2012, "Path-breaking innovations for lung cancer: a revolution in clinical practice," CERIS Working Paper, CNR-IRCrES Research Institute on Sustainable Economic Growth - Torino (TO) ITALY - former Institute for Economic Research on Firms and Growth - Moncalieri (TO) ITALY, number 201201, Jun.
• Mainak Mazumdar & Meenakshi Rajeev & Subhash C. Ray, 2012, "Sources of Heterogeneity in the Efficiency of Indian Pharmaceutical Firms," Indian Economic Review, Department of Economics, Delhi School of Economics, volume 47, issue 2, pages 191-221.
• Sarbapriya Ray, 2012, "Productivity Growth in Some Energy Intensive Manufacturing Industries in India: An Analytical Assessment," International Journal of Economics and Financial Issues, Econjournals, volume 2, issue 1, pages 54-70.
• Hellerstein, Rebecca, 2012, "What do drug monopolies cost consumers in developing countries?," Economics Letters, Elsevier, volume 116, issue 1, pages 108-111, DOI: 10.1016/j.econlet.2011.12.114.
• Toole, Andrew A., 2012, "The impact of public basic research on industrial innovation: Evidence from the pharmaceutical industry," Research Policy, Elsevier, volume 41, issue 1, pages 1-12, DOI: 10.1016/j.respol.2011.06.004.
• Santiago, Fernando & Alcorta, Ludovico, 2012, "Human resource management for learning through knowledge exploitation and knowledge exploration: Pharmaceuticals in Mexico," Structural Change and Economic Dynamics, Elsevier, volume 23, issue 4, pages 530-546, DOI: 10.1016/j.strueco.2011.11.002.
• Carrère, Céline & de Melo, Jaime, 2012, "Fiscal Spending and Economic Growth: Some Stylized Facts," World Development, Elsevier, volume 40, issue 9, pages 1750-1761, DOI: 10.1016/j.worlddev.2012.04.011.
• Gaston Heimeriks & Ron Boschma, 2012, "The path- and place-dependent nature of scientific knowledge production in biotech 1986-2008," Papers in Evolutionary Economic Geography (PEEG), Utrecht University, Department of Human Geography and Spatial Planning, Group Economic Geography, number 1210, Jun, revised Jun 2012.
• Patricia M. Danzon & Andrew J. Epstein, 2012, "Effects of Regulation on Drug Launch and Pricing in Interdependent Markets," Advances in Health Economics and Health Services Research, Emerald Group Publishing Limited, "The Economics of Medical Technology", DOI: 10.1108/S0731-2199(2012)0000023005.
• Frank R. Lichtenberg, 2012, "The Effect of Pharmaceutical Innovation on the Functional Limitations of Elderly Americans: Evidence from the 2004 National Nursing Home Survey," Advances in Health Economics and Health Services Research, Emerald Group Publishing Limited, "The Economics of Medical Technology", DOI: 10.1108/S0731-2199(2012)0000023006.
• Maria Letizia Giorgetti, 2012, "Entry and submarket concentration: empirical evidence from the pharmaceutical industry," ECONOMIA E POLITICA INDUSTRIALE, FrancoAngeli Editore, volume 2012, issue 3, pages 5-29.
• Hokkanen, Joni & Kangasharju, Aki & Linnosmaa, Ismo & Valtonen, Hannu, 2012, "Generic substitution policy, prices and market structure: evidence from a quasi-experiment in Finland," Working Papers, VATT Institute for Economic Research, number 35.
• Marianna EPICOCO & Vanessa OLTRA & Maïder SAINT JEAN, 2012, "Mapping the scientific knowledge of the Green Chemistry community (In French)," Cahiers du GREThA (2007-2019), Groupe de Recherche en Economie Théorique et Appliquée (GREThA), number 2012-10.
• Vanessa OLTRA & Maïder SAINT-JEAN, 2012, "Regional trajectories of innovation in Green Chemistry: Evidence from the Aquitaine region (In French)," Cahiers du GREThA (2007-2019), Groupe de Recherche en Economie Théorique et Appliquée (GREThA), number 2012-14.
• Christian Garavaglia & Michele Pezzoni & Luigi Orsenigo & Franco Malerba, 2012, "Technological regimes and demand structure in the evolution of the pharmaceutical industry," Post-Print, HAL, number halshs-01074513, DOI: 10.1007/s00191-012-0285-1.
• Granlund, David & Yesim Köksal, Miyase, 2012, "EU Enlargement, Parallel Trade and Price Competition in Pharmaceuticals - What’s to Blame? Derogation or Perception?," HUI Working Papers, HUI Research, number 59, Mar.
• Granlund, David, 2012, "The effect of pharmacies’ right to negotiate discounts on the market share of parallel imported pharmaceuticals," HUI Working Papers, HUI Research, number 75, Nov.
• Granlund, David, 2012, "The effect of pharmacies’ right to negotiate discounts on the market share of parallel imported pharmaceuticals," Umeå Economic Studies, Umeå University, Department of Economics, number 853, Nov.
• Berndt, Ernst R. & Dubois, Pierre, 2012, "Impacts of Patent Expiry and Regulatory Policies on Daily Cost of Pharmaceutical Treatments: OECD Countries, 2004-2010," IDEI Working Papers, Institut d'Économie Industrielle (IDEI), Toulouse, number 702, Mar.
• Christine Sorasith & Sylvain Pichetti & Thomas Cartier & Laure Bergua & Catherine Sermet, 2012, "Déterminants de l’écart de prix entre médicaments similaires et le premier entrant d’une classe thérapeutique," Working Papers, IRDES institut for research and information in health economics, number DT43, Feb, revised Feb 2012.
• Luiz Flavio Andrade, 2012, "Entry Time Effects and Follow-on Drugs Competition," Working Papers, IRDES institut for research and information in health economics, number DT49, Jun, revised Jun 2012.
• Nicola Dimitri, 2012, "R&D for Neglected Diseases," Working Papers, Maastricht School of Management, number 2012/07, Jun.
• Frank R. Lichtenberg, 2012, "The Effect of Pharmaceutical Innovation on the Functional Limitations of Elderly Americans Evidence from the 2004 National Nursing Home Survey," NBER Working Papers, National Bureau of Economic Research, Inc, number 17750, Jan.
• Bret M. Dickey & Daniel L. Rubinfeld, 2012, "Would The Per Se Illegal Treatment Of Reverse Payment Settlements Inhibit Generic Drug Investment?," Journal of Competition Law and Economics, Oxford University Press, volume 8, issue 3, pages 615-625.
• Mohammad Al-Tahat & Areen Al-Ali, 2012, "Energy saving opportunities in Jordanian pharmaceutical industries," Perspectives of Innovation in Economics and Business (PIEB), Prague Development Center, volume 10, issue 1, pages 35-50, May.
• Kamal A. M. Al-Qudah, 2012, "The Impact Of Total Quality Management On Competitive Advantage Of Pharmaceutical Manufacturing Companies In Jordan," Perspectives of Innovation in Economics and Business (PIEB), Prague Development Center, volume 12, issue 3, pages 59-75, November.
• Anderson, Simon & Ciliberto, Federico & Liaukonyte, Jura & Renault, Regis, 2012, "Push-Me Pull-You: Comparative Advertising in the OTC Analgesics Industry," MPRA Paper, University Library of Munich, Germany, number 38626, Apr.
• Cassi, Lorenzo & Plunket, Anne, 2012, "Research collaboration in co-­inventor networks: combining closure,bridging and proximities," MPRA Paper, University Library of Munich, Germany, number 39481, May.
• Hernesniemi, Hannu & Kulvik, Martti & Ylä-Anttila, Pekka, 2012, "Competitiveness and future challenges of Pohjois-Savo - A report for The Regional Council of Pohjois-Savo (in Finnish with English abstract and summary)," Discussion Papers, The Research Institute of the Finnish Economy, number 1281.
• Samia GHARBI, 2012, "Le rôle de l’Etat dans la promotion du secteur pharmaceutique en Algérie: que nous enseigne l’approche par les systèmes sectoriels d’innovation THE ROLE OF THE STATE IN THE PROMOTION OF THE PHARMACEUT," Working Papers, Laboratoire de Recherche sur l'Industrie et l'Innovation. ULCO / Research Unit on Industry and Innovation, number 258, Sep.
• Lorenzo Carbonari, 2012, "Quasi-fixed inputs in the Italian manufacturing: The case of the pharmaceutical industry," Applied Econometrics, Russian Presidential Academy of National Economy and Public Administration (RANEPA), volume 25, issue 1, pages 51-69.
• Ravi MAHALINGAM, 2012, "Dynamics of Public Policy-Making in Malaysia: The Formulation of National Biotechnology Policy," REVISTA ADMINISTRATIE SI MANAGEMENT PUBLIC, Faculty of Administration and Public Management, Academy of Economic Studies, Bucharest, Romania, volume 2012, issue 19, pages 53-61, December.
• Rosamaria D'Amore & Roberto Iorio & Agnieszka Stawinoga, 2012, "Who and Where are the Co-Authors? The Relationship between Institutional and Geographical Distance in Scientific Publications," Working Papers, Dipartimento di Scienze Economiche e Statistiche, Università degli Studi di Salerno, number 3_221, Aug.
• Rosamaria D'Amore & Roberto Iorio & Sandrine Labory & Agnieszka Stawinoga, 2012, "How Do the Institutions Involved in Scientific Collaboration Deal with Different Kinds of Distance? An Analysis of the Co-Autorships of Scientific Publications," Working Papers, Dipartimento di Scienze Economiche e Statistiche, Università degli Studi di Salerno, number 3_222, Aug.
• Roger Noll & Paul, 2012, "Alfred E. Kahn 1917-2010," Discussion Papers, Stanford Institute for Economic Policy Research, number 11-021, Aug.
• Nathan Rosenberg & W. Edward Steinmuller, 2012, "Engineering Knowledge," Discussion Papers, Stanford Institute for Economic Policy Research, number 11-022, Aug.
• Steven Edwards & Sarah Wordsworth & Mike Clarke, 2012, "Treating pneumonia in critical care in the United Kingdom following failure of initial antibiotic: a cost-utility analysis comparing meropenem with piperacillin/tazobactam," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), volume 13, issue 2, pages 181-192, April, DOI: 10.1007/s10198-011-0296-0.
• Christian Garavaglia & Franco Malerba & Luigi Orsenigo & Michele Pezzoni, 2012, "Technological regimes and demand structure in the evolution of the pharmaceutical industry," Journal of Evolutionary Economics, Springer, volume 22, issue 4, pages 677-709, September, DOI: 10.1007/s00191-012-0285-1.
• Ramazan Uctu & Hassan Essop, 2012, "The Role of the South African Government in Developing the Biotechnology Industry – from Biotechnology Regional Innovation Centres to the Technology Innovation Agency," Working Papers, Stellenbosch University, Department of Economics, number 19/2012.
• Jean-Marie Grether & Nicole Andr�a Mathys & Jaime de Melo, 2012, "Unravelling the worldwide pollution haven effect," The Journal of International Trade & Economic Development, Taylor & Francis Journals, volume 21, issue 1, pages 131-162, December, DOI: 10.1080/09638190903552040.
• Margaret K. Kyle & Anita M. McGahan, 2012, "Investments in Pharmaceuticals Before and After TRIPS," The Review of Economics and Statistics, MIT Press, volume 94, issue 4, pages 1157-1172, November.
• Berndt, Ernst R. & Dubois, Pierre, 2012, "Impacts of Patent Expiry and Regulatory Policies on Daily Cost of Pharmaceutical Treatments: OECD Countries, 2004-2010," TSE Working Papers, Toulouse School of Economics (TSE), number 12-283, Mar.
• Jaume Puig & Beatriz González López-Valcárcel, 2012, "Launching prices for new pharmaceuticals in heavily regulated and subsidized markets," Economics Working Papers, Department of Economics and Business, Universitat Pompeu Fabra, number 1322, May.
• Kirchhoff, Jasmina, 2012, "Wissensbasis und regionale Agglomeration: Zwei Pharmacluster im Vergleich," IW-Trends – Vierteljahresschrift zur empirischen Wirtschaftsforschung, Institut der deutschen Wirtschaft (IW) / German Economic Institute, volume 39, issue 4, pages 89-104, DOI: 10.2373/1864-810X.12-04-06.

2011

• Joseph E. Harrington & Andrzej Skrzypacz, 2011, "Private Monitoring and Communication in Cartels: Explaining Recent Collusive Practices," American Economic Review, American Economic Association, volume 101, issue 6, pages 2425-2449, October.
• Glenn Ellison & Sara Fisher Ellison, 2011, "Strategic Entry Deterrence and the Behavior of Pharmaceutical Incumbents Prior to Patent Expiration," American Economic Journal: Microeconomics, American Economic Association, volume 3, issue 1, pages 1-36, February.
• Catherine Thomas, 2011, "Too Many Products: Decentralized Decision Making in Multinational Firms," American Economic Journal: Microeconomics, American Economic Association, volume 3, issue 1, pages 280-306, February.
• Kensuke Kubo, 2011, "Explaining vertical integration in the generic pharmaceutical industry," Discussion Papers, Indian Statistical Institute, Delhi, number 11-02, Feb.
• Guanming Shi & Kyle W. Stiegert & Jean P. Chavas, 2011, "An analysis of bundle pricing in horizontal and vertical markets: The case of the U.S. cottonseed market," Agricultural Economics, International Association of Agricultural Economists, volume 42, issue , pages 77-88, November, DOI: j.1574-0862.2011.00553.x.
• Berndt Ernst R. & McGuire Thomas & Newhouse Joseph P., 2011, "A Primer on the Economics of Prescription Pharmaceutical Pricing in Health Insurance Markets," Forum for Health Economics & Policy, De Gruyter, volume 14, issue 1, pages 1-30, November, DOI: 10.2202/1558-9544.1301.
• Claudia Nelcy Jiménez Hernández, 2011, "Seguimiento al desarrollo tecnológico a través de patentes el caso de la biotecnología," Documentos de Trabajo, Escuela de Economía, Universidad Nacional de Colombia, FCE, CID, number 8843, Jul.
• Kyle, Margaret & Allain, Marie-Laure, 2011, "Inefficiencies in technology transfer: theory and empirics," CEPR Discussion Papers, C.E.P.R. Discussion Papers, number 8206, Jan.
• Seabright, Paul & Scott Morton, Fiona & Dubois, Pierre & de Mouzon, Olivier, 2011, "Market Size and Pharmaceutical Innovation," CEPR Discussion Papers, C.E.P.R. Discussion Papers, number 8367, Apr.
• Kyle, Margaret & McGahan, Anita M, 2011, "Investments in Pharmaceuticals Before and After TRIPS," CEPR Discussion Papers, C.E.P.R. Discussion Papers, number 8371, May.
• Paraskevopoulou, Evita, 2011, "On the institutional innovation process : EU regulation through an evolutionary lens," DEE - Working Papers. Business Economics. WB, Universidad Carlos III de Madrid. Departamento de Economía de la Empresa, number wb111305, Apr.
• Scott Morton, Fiona & Kyle, Margaret, 2011, "Markets for Pharmaceutical Products11The authors thank Tom McGuire for editorial advice and improvements and participants at the Handbook conference for helpful suggestions," Handbook of Health Economics, Elsevier, chapter 0, in: Mark V. Pauly & Thomas G. Mcguire & Pedro P. Barros, "Handbook of Health Economics", DOI: 10.1016/B978-0-444-53592-4.00012-8.
• Bhattacharya, Jay & Packalen, Mikko, 2011, "Opportunities and benefits as determinants of the direction of scientific research," Journal of Health Economics, Elsevier, volume 30, issue 4, pages 603-615, July.
• Brekke, Kurt R. & Holmas, Tor Helge & Straume, Odd Rune, 2011, "Reference pricing, competition, and pharmaceutical expenditures: Theory and evidence from a natural experiment," Journal of Public Economics, Elsevier, volume 95, issue 7-8, pages 624-638, August.
• Brekke, Kurt R. & Holmas, Tor Helge & Straume, Odd Rune, 2011, "Reference pricing, competition, and pharmaceutical expenditures: Theory and evidence from a natural experiment," Journal of Public Economics, Elsevier, volume 95, issue 7, pages 624-638, DOI: 10.1016/j.jpubeco.2010.11.015.
• Kolympiris, Christos & Kalaitzandonakes, Nicholas & Miller, Douglas, 2011, "Spatial collocation and venture capital in the US biotechnology industry," Research Policy, Elsevier, volume 40, issue 9, pages 1188-1199, DOI: 10.1016/j.respol.2011.05.022.
• Anne L.J. Ter Wal, 2011, "The Dynamics of the Inventor Network in German Biotechnology: Geographical Proximity versus Triadic Closure," Papers in Evolutionary Economic Geography (PEEG), Utrecht University, Department of Human Geography and Spatial Planning, Group Economic Geography, number 1102, Jan, revised Jan 2011.
• Rebecca Hellerstein, 2011, "What do drug monopolies cost consumers in developing countries?," Staff Reports, Federal Reserve Bank of New York, number 530, Dec.
• Begoña Garcia Mariñoso & Izabela Jelovac & Pau Olivella, 2011, "External referencing and pharmaceutical price negotiation," Post-Print, HAL, number halshs-00303682, DOI: 10.1002/hec.1630.
• Luiz Flavio Andrade, 2011, "Entry time effects and follow on drug competition," Post-Print, HAL, number halshs-00658247, Jun.
• Marie-Laure Allain & Emeric Henry & Margaret Kyle, 2011, "Inefficiencies in technology transfer: theory and empirics," Sciences Po Economics Publications (main), HAL, number hal-03473787, Jan.
• Marie-Laure Allain & Emeric Henry & Margaret Kyle, 2011, "Inefficiencies in technology transfer: theory and empirics," Working Papers, HAL, number hal-03473787, Jan.
• Julien Gourdon & Nicolas Maystre & Jaime Melo De, 2011, "Openness, Inequality, and Poverty: Endowments Matter," Working Papers, HAL, number halshs-00557112, Jan.
• Granlund, David & Yesim Köksal, Miyase, 2011, "Parallel Imports and Mandatory Substitution Reform: A kick or a muff for price competition in pharmaceuticals," Working Papers in Economics, University of Gothenburg, Department of Economics, number 496, Apr.
• Granlund, David & Yesim Köksal, Miyase, 2011, "EU Enlargement, Parallel Trade and Price Competition in Pharmaceuticals. What's blame? Derogation or perception?," Working Papers in Economics, University of Gothenburg, Department of Economics, number 499, May.
• Carlsson, Fredrik & Lampi, Elina & Li, Wanxin & Martinsson, Peter, 2011, "Subjective well-being among preadolescents - Evidence from urban China," Working Papers in Economics, University of Gothenburg, Department of Economics, number 500, May.
• Granlund, David & Köksal, Miyase Yesim, 2011, "Parallel Imports and Mandatory Substitution Reform - A Kick or A Muff for Price Competition in Pharmaceuticals?," HUI Working Papers, HUI Research, number 49, Apr.
• Granlund, David & Köksal , Miyase Yesim, 2011, "Parallel Imports and Mandatory Substitution Reform - A Kick or A Muff for Price Competition in Pharmaceuticals?," Umeå Economic Studies, Umeå University, Department of Economics, number 824, Apr.
• Granlund, David & Yesim Köksal, Miyase, 2011, "EU Enlargement, Parallel Trade and Price Competition in Pharmaceuticals - What’s to Blame? Derogation or Perception?," Umeå Economic Studies, Umeå University, Department of Economics, number 831, Sep.
• Dubois, Pierre & de Mouzon, Olivier & Scott Morton, Fiona & Seabright, Paul, 2011, "Market Size and Pharmaceutical Innovation," IDEI Working Papers, Institut d'Économie Industrielle (IDEI), Toulouse, number 670, Apr, revised Mar 2014.
• Rosamaria d’Amore & Roberto Iorio & Agnieszka Stawinoga, 2011, "Who and where are the co-authors? The relationship between institutional and geographical distance in scientific publications," Working Papers, International Network for Economic Research - INFER, number 2011.4.
• Vernon Somerset (ed.), 2011, "Environmental Biosensors," Books, IntechOpen, number 1018, ISBN: ARRAY(0x98ea63e0), June, DOI: 10.5772/929.
• Peilei Fan, 2011, "Innovation capacity and economic development: China and India," Economic Change and Restructuring, Springer, volume 44, issue 1, pages 49-73, April, DOI: 10.1007/s10644-010-9088-2.
• Aysegul Timur & Gabriel Picone & Jeffrey DeSimone, 2011, "Has the European union achieved a single pharmaceutical market?," International Journal of Health Economics and Management, Springer, volume 11, issue 4, pages 223-244, December, DOI: 10.1007/s10754-011-9100-z.
• Cédric Schneider, 2011, "The battle for patent rights in plant biotechnology: evidence from opposition fillings," The Journal of Technology Transfer, Springer, volume 36, issue 5, pages 565-579, October, DOI: 10.1007/s10961-010-9200-9.
• Dragan Kesic, 2011, "Strategic Development Trends in the World Pharmaceutical Industry," Managing Global Transitions, University of Primorska, Faculty of Management Koper, volume 9, issue 3, pages 207-223.
• Roberto Iorio & Sandrine Labory & Daniele Paci, 2012, "Research Collaboration and Publication's Citation Impact: Evidence in the Italian Biotech Sector," Rivista italiana degli economisti, Società editrice il Mulino, issue 1, pages 75-100.
• Ernst R. Berndt & Thomas G. McGuire & Joseph P. Newhouse, 2011, "A Primer on the Economics of Prescription Pharmaceutical Pricing in Health Insurance Markets," NBER Working Papers, National Bureau of Economic Research, Inc, number 16879, Mar.
• Patricia M. Danzon & Michael F. Furukawa, 2011, "Cross-National Evidence on Generic Pharmaceuticals: Pharmacy vs. Physician-Driven Markets," NBER Working Papers, National Bureau of Economic Research, Inc, number 17226, Jul.
• Nobuo Kiriyama, 2011, "Trade and Innovation: Pharmaceuticals," OECD Trade Policy Papers, OECD Publishing, number 113, Apr, DOI: 10.1787/5kgdscrcv7jg-en.
• Unita Lucian & Straciuc Oreste & Maghiar Teodor Traian & Uivarosan Diana, 2011, "The Production Of Medicines In Romania After 1990. What'S The Reason For Imports?," Annals of Faculty of Economics, University of Oradea, Faculty of Economics, volume 1, issue 2, pages 124-130, December.
• Ijaz Hussain, 2011, "Growth and Financing Behaviour of Firms of Textile Industry in Pakistan: A Panel Data Analysis," The Pakistan Development Review, Pakistan Institute of Development Economics, volume 50, issue 4, pages 699-714.
• Massimo, Riccaboni & Jakub, Growiec & Fabio, Pammolli, 2011, "Innovation and Corporate Dynamics: A Theoretical Framework," MPRA Paper, University Library of Munich, Germany, number 30046, Mar.
• Morales, Eduardo & Sheu, Gloria & Zahler, Andrés, 2011, "Gravity and extended gravity: estimating a structural model of export entry," MPRA Paper, University Library of Munich, Germany, number 30311, Jan.
• Ohta, Hirofumi & Motohashi, Kazuyuki, 2011, "Accumulation and Circulation of the Knowledge Needed for Biotech Business Promotion by Engineers of R&D Section in an IT Enterprise: The Case of Hitachi Software Engineering Co., Ltd," MPRA Paper, University Library of Munich, Germany, number 50097, Dec.
• Plawgo, Bogusław & Klimczuk-Kochańska, Magdalena & Żynel-Etel, Justyna & Wyszkowski, Adam, 2011, "Startery podlaskiej gospodarki - analiza gospodarczych obszarów wzrostu i innowacji województwa podlaskiego. Sektor biotechnologii
  [Starters of the Podlasie Economy: Analysis of Economic Areas of Growth and Innovation in the Podlaskie region: The ," MPRA Paper, University Library of Munich, Germany, number 85003.
• Saradindu Bhaduri & Thomas Brenner, 2011, "Determinants of drug launch delay in pre-TRIPS India: A survival analysis approach," Working Papers on Innovation and Space, Philipps University Marburg, Department of Geography, number 2011-05, Dec.
• Marc-André Gagnon, 2011, "Marx’s social analysis of value and Big Pharma. Rethinking the social determinants of value in cognitive capitalism," European Journal of Economic and Social Systems, Lavoisier, volume 24, issue 1-2, pages 119-136.
• Sarbapriya, Ray & Mihir, Kumar Pal, 2011, "An Application of Economic Capacity Utilization to the Measurement of Total Factor Productivity Growth: Empirical Evidence from Indian Fertilizer Industry," Journal for Economic Forecasting, Institute for Economic Forecasting, volume 0, issue 1, pages 125-142, March.
• Alessandro Rosiello & Gil Avnimelech & Morris Teubal, 2011, "Towards a systemic and evolutionary framework for venture capital policy," Journal of Evolutionary Economics, Springer, volume 21, issue 1, pages 167-189, February, DOI: 10.1007/s00191-010-0189-x.
• M. Laura Frigotto & Massimo Riccaboni, 2011, "A few special cases: scientific creativity and network dynamics in the field of rare diseases," Scientometrics, Springer;Akadémiai Kiadó, volume 89, issue 1, pages 397-420, October, DOI: 10.1007/s11192-011-0431-9.
• Marc-Hubert DEPRET & Abdelillah HAMDOUCH, 2011, "Multiscalar Clusters And Networks As The Foundations Of Innovation Dynamics In The Biopharmaceutical Industry," Region et Developpement, Region et Developpement, LEAD, Universite du Sud - Toulon Var, volume 33, pages 227-268.
• Massimo Riccaboni & Maria Laura Frigotto, 2011, "A Few Special Cases: Scientific Creativity and Network Dynamics in the Field of Rare Diseases," DISA Working Papers, Department of Computer and Management Sciences, University of Trento, Italy, number 2011/03, Mar, revised 24 May 2011.
• Jakub Growiec & Fabio Pammolli & Massimo Riccaboni, 2011, "Innovation and Corporate Dynamics: A Theoretical Framework," DISA Working Papers, Department of Computer and Management Sciences, University of Trento, Italy, number 2011/08, Aug, revised 29 Jul 2011.
• Dubois, Pierre & de Mouzon, Olivier & Scott Morton, Fiona & Seabright, Paul, 2011, "Market Size and Pharmaceutical Innovation," TSE Working Papers, Toulouse School of Economics (TSE), number 11-232, Apr, revised Mar 2014.
• Mainak Mazumdar & Meenakshi Rajeev & Subhash Ray, 2011, "Sources of Heterogeneity in the Efficiency of Indian Pharmaceutical Firms," Working papers, University of Connecticut, Department of Economics, number 2011-22, Nov.
• Wang, Lili & Notten, Ad, 2011, "Mapping the interdisciplinary nature and co-evolutionary patterns in five nano-industrial sectors," MERIT Working Papers, United Nations University - Maastricht Economic and Social Research Institute on Innovation and Technology (MERIT), number 2011-029.
• Daems, Rutger & Maes, Edith & Ramani, Shyama V., 2011, "Global Framework for Differential Pricing of Pharmaceuticals," MERIT Working Papers, United Nations University - Maastricht Economic and Social Research Institute on Innovation and Technology (MERIT), number 2011-054.
• Begoña Garcia Mariñoso & Izabela Jelovac & Pau Olivella, 2011, "External referencing and pharmaceutical price negotiation," Health Economics, John Wiley & Sons, Ltd., volume 20, issue 6, pages 737-756, June, DOI: 10.1002/hec.1630.
• Ivan Moreno-Torres, 2011, "What if there was a stronger pharmaceutical price competition in Spain? When regulation has a similar effect to collusion," Working Papers, Xarxa de Referència en Economia Aplicada (XREAP), number XREAP2011-02, May, revised May 2011.
• Ivan Moreno-Torres, 2011, "Generic drugs in Spain: price competition vs. moral hazard," Working Papers, Xarxa de Referència en Economia Aplicada (XREAP), number XREAP2011-04, May, revised May 2011.
• Krogmann, Yin & Schwalbe, Ulrich, 2011, "Inter-firm R&D networks in the global pharmaceutical biotechnology industry during 1985 - 1998: A conceptual and empirical analysis," FZID Discussion Papers, University of Hohenheim, Center for Research on Innovation and Services (FZID), number 38-2011.
• Toole, Andrew A., 2011, "The impact of public basic research on industrial innovation: Evidence from the pharmaceutical industry," ZEW Discussion Papers, ZEW - Leibniz Centre for European Economic Research, number 11-063.

2010

• Artjoms Ivlevs & Jaime De Melo, 2010, "FDI, the Brain Drain and Trade: Channels and Evidence," Annals of Economics and Statistics, GENES, issue 97-98, pages 103-121.
• Josh Lerner & Ulrike Malmendier, 2010, "Contractibility and the Design of Research Agreements," American Economic Review, American Economic Association, volume 100, issue 1, pages 214-246, March.
• Angus Deaton, 2010, "Price Indexes, Inequality, and the Measurement of World Poverty," American Economic Review, American Economic Association, volume 100, issue 1, pages 5-34, March.
• Mark Duggan & Fiona Scott Morton, 2010, "The Effect of Medicare Part D on Pharmaceutical Prices and Utilization," American Economic Review, American Economic Association, volume 100, issue 1, pages 590-607, March.
• Hal R. Varian, 2010, "Computer Mediated Transactions," American Economic Review, American Economic Association, volume 100, issue 2, pages 1-10, May, DOI: 10.1257/aer.100.2.1.
• Joachim Henkel & Stephen M. Maurer, 2010, "Network Effects in Biology R&D," American Economic Review, American Economic Association, volume 100, issue 2, pages 159-164, May, DOI: 10.1257/aer.100.2.159.
• Seema Jayachandran & Adriana Lleras-Muney & Kimberly V. Smith, 2010, "Modern Medicine and the Twentieth Century Decline in Mortality: Evidence on the Impact of Sulfa Drugs," American Economic Journal: Applied Economics, American Economic Association, volume 2, issue 2, pages 118-146, April.
• Guy David & Sara Markowitz & Seth Richards-Shubik, 2010, "The Effects of Pharmaceutical Marketing and Promotion on Adverse Drug Events and Regulation," American Economic Journal: Economic Policy, American Economic Association, volume 2, issue 4, pages 1-25, November.
• Xu, Zheng & Hennessy, David A. & Moschini, GianCarlo, 2010, "Have Biotech Seeds Increased Maize Yields?," 2010 Annual Meeting, July 25-27, 2010, Denver, Colorado, Agricultural and Applied Economics Association, number 61303, DOI: 10.22004/ag.econ.61303.
• Shi, Guanming & Chavas, Jean-Paul, 2010, "Pricing and Vertical Organization of Differentiated Products," Staff Papers, University of Wisconsin-Madison, Department of Agricultural and Applied Economics, number 92228, DOI: 10.22004/ag.econ.92228.
• Vlatka Bilas & Vedran Baci, 2010, "The Influence Of The Acquisition Experience On The Successfulness Of International Mergers And Acquisitions In Pharmaceutical Industry 2003-2009," Economic Thought and Practice, Department of Economics and Business, University of Dubrovnik, volume 19, issue 2, pages 187-209, december.
• Frank Lichtenberg, 2010, "The Contribution of Pharmaceutical Innovation to Longevity Growth in Germany and France," CESifo Working Paper Series, CESifo, number 3095.
• Dag Morten Dalen & Marilena Locatelli & Steinar Strøm, 2010, "Longitudinal Analysis of Generic Substitution," CESifo Working Paper Series, CESifo, number 3176.
• Kurt R. Brekke & Tor Helge Holmås & Odd Rune Straume, 2010, "Reference Pricing, Competition, and Pharmaceutical Expenditures: Theory and Evidence from a Natural Experiment," CESifo Working Paper Series, CESifo, number 3258.
• Mathias Kifmann & Sven Neelsen, 2010, "Germany's Struggle with Prices for Patent-protected Drugs," ifo DICE Report, ifo Institute - Leibniz Institute for Economic Research at the University of Munich, volume 8, issue 03, pages 43-52, October.
• Siotis, Georges & de Frutos, Maria-Angeles & Ornaghi, Carmine, 2010, "Competition in the Pharmaceutical Industry: How do Quality Differences Shape Advertising Strategies?," CEPR Discussion Papers, C.E.P.R. Discussion Papers, number 8076, Oct.
• Christian Garavaglia & Franco Malerba & Luigi Orsenigo & Michele Pezzoni, 2010, "A History-Friendly Model of the Evolution of the Pharmaceutical Industry: Technological Regimes and Demand Structure," KITeS Working Papers, KITeS, Centre for Knowledge, Internationalization and Technology Studies, Universita' Bocconi, Milano, Italy, number 036, Nov, revised Nov 2010.
• Anne Boring, 2010, "Political contributions to influence consumers: the example of the u.s. drug reimportation debate," Working Papers, DIAL (Développement, Institutions et Mondialisation), number DT/2010/03, Jan.
• Berndt, Ernst R. & Newhouse, Joseph P., 2010, "Pricing and Reimbursement in U.S. Pharmaceutical Markets," Working Paper Series, Harvard University, John F. Kennedy School of Government, number rwp10-039, Sep.
• Ching, Andrew T., 2010, "Consumer learning and heterogeneity: Dynamics of demand for prescription drugs after patent expiration," International Journal of Industrial Organization, Elsevier, volume 28, issue 6, pages 619-638, November.
• Capelle-Blancard, Gunther & Laguna, Marie-Aude, 2010, "How does the stock market respond to chemical disasters?," Journal of Environmental Economics and Management, Elsevier, volume 59, issue 2, pages 192-205, March.
• Frank R. Lichtenberg, 2010, "The effect of drug vintage on survival: Micro evidence from Puerto Rico's Medicaid program," Advances in Health Economics and Health Services Research, Emerald Group Publishing Limited, "Pharmaceutical Markets and Insurance Worldwide", DOI: 10.1108/S0731-2199(2010)0000022015.
• Subhash C Ray & Mainak Mazumdar & Meenakshi Rajeev, 2010, "Sources of Heterogeneity in the Efficiency of Indian Pharmaceutical Firms," Working Papers, eSocialSciences, number id:3334, Dec.
• Marie-Aude Laguna & Gunther Capelle-Blancard, 2010, "How Does the Stock Market Respond to Chemical Disasters?," Université Paris1 Panthéon-Sorbonne (Post-Print and Working Papers), HAL, number halshs-00637961, Mar, DOI: 10.1016/j.jeem.2009.11.002.
• Michel Trommetter, 2010, "Flexibility in the implementation of intellectual property rights in agricultural biotechnology," Post-Print, HAL, number hal-02665179, DOI: 10.1007/s10657-009-9133-7.
• Marie-Aude Laguna & Gunther Capelle-Blancard, 2010, "How Does the Stock Market Respond to Chemical Disasters?," Post-Print, HAL, number halshs-00637961, Mar, DOI: 10.1016/j.jeem.2009.11.002.
• Begoña Garcia Mariñoso & Izabela Jelovac & Pau Olivella, 2010, "External referencing and pharmaceutical price negotiation," Post-Print, HAL, number halshs-00955856.
• Schneider, Cédric, 2010, "The Battle for Patent Rights in Plant Biotechnology: Evidence from Opposition," Working Papers, Copenhagen Business School, Department of Economics, number 06-2010, Jun.
• Brekke, Kurt Richard & Holmås, Tor Helge & Straume, Odd Rune, 2010, "Margins and Market Shares: Pharmacy Incentives for Generic Substitution," Discussion Paper Series in Economics, Norwegian School of Economics, Department of Economics, number 18/2010, Jul.
• Newhouse, Joseph Paul & Berndt, Ernst R., 2010, "Pricing and Reimbursement in U.S. Pharmaceutical Markets," Scholarly Articles, Harvard Kennedy School of Government, number 4450127.
• Junichi Nishimura & Yosuke Okada, 2010, "R&D Portfolios and Pharmaceutical Licensing," Global COE Hi-Stat Discussion Paper Series, Institute of Economic Research, Hitotsubashi University, number gd10-155, Nov.
• Andrew T. Ching, 2010, "A Dynamic Oligopoly Structural Model For The Prescription Drug Market After Patent Expiration," International Economic Review, Department of Economics, University of Pennsylvania and Osaka University Institute of Social and Economic Research Association, volume 51, issue 4, pages 1175-1207, November.
• Victor Platon & Simona Frone & Andreea Constantinescu & Sorina Jurist, 2010, "Current Perspectives and Challenges of Biofuel Production and Consumption," Romanian Journal of Economics, Institute of National Economy, volume 31, issue 2(40), pages 107-128, December.